TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysis.
TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysis.
复制标题
DOI：
10.3892/ol.2017.6467
复制
发表时间：
2017-08
期刊：
影响因子：
2.9
通讯作者：
Xi X
中科院分区：
文献类型：
--
作者：
Hao L;Du B;Xi X
肺癌是世界范围内癌症相关死亡率的主要原因，其预后很差。非小细胞肺癌（NSCLC）的有效生物标志物很少被转化为临床实践，旨在帮助治疗方案设计和预后评估。本研究的目的是确定新的潜在的NSCLC预后生物标志物。从匹配样本的微阵列数据集中鉴定了三分基序59（TRIM 59），并证实其为NSCLC组织中异常上调的基因。TRIM 59在NSCLC各亚型中的表达水平在大细胞肺癌和鳞状细胞癌中显著高于腺癌。它的表达与一些临床病理特征相关，包括性别、吸烟习惯、不利的肿瘤淋巴结和病理分期。值得注意的是，TRIM 59与生存时间呈负相关，其过表达表明NSCLC预后不良。单因素和多因素考克斯回归分析表明，TRIM 59与年龄、性别、肿瘤分期、淋巴结分期和转移相比，是肿瘤组织中的独立预后因素。基因集富集分析和蛋白质-蛋白质相互作用网络构建揭示TRIM 59通过泛素C结合与致癌哺乳动物雷帕霉素靶蛋白（MTOR）和真核生物起始因子4 E（EIF 4 E）信号传导相关。总之，揭示了TRIM 59是调节NSCLC中致癌MTOR和EIF 4 E信号传导途径的新型预后生物标志物。这些发现为TRIM 59的临床应用提供了新的见解。因此，TRIM 59可能作为一个独立的预后预测因子和一个潜在的NSCLC治疗靶点。
Lung cancer is the leading cause of cancer-associated mortality worldwide and its prognosis is poor. Few effective biomarkers for non-small cell lung cancer (NSCLC) have been translated into the clinical practice aiming to assist in the treatment plan design and prognosis evaluation. The aim of the present study was to identify novel potential prognostic biomarkers for NSCLC. Tripartite motif 59 (TRIM59) was identified from a microarray dataset of matched-samples and was verified as an aberrantly upregulated gene in NSCLC tissue. The expression level of TRIM59 in NSCLC subtypes was observed to be significantly increased in large cell lung carcinoma and squamous cell carcinoma as compared with that in adenocarcinoma. Its expression correlated with several clinicopathological features, including gender, smoking habits, and unfavorable tumor node and pathological stages. Notably, TRIM59 demonstrated a negative correlation with survival time and its overexpression indicated a poor prognosis in NSCLC. Furthermore, univariate and multivariate Cox's regression analyses indicated that TRIM59 was an independent prognostic factor in tumor tissue as compared with age, gender, tumor stage, node stage, and metastasis. Gene set enrichment analysis and protein-protein interaction network construction revealed that TRIM59 was associated with oncogenic mammalian target of rapamycin (MTOR) and eukaryotic initiation factor 4E (EIF4E) signaling through ubiquitin C binding. In conclusion, it was revealed that TRIM59 is a novel prognostic biomarker modulating oncogenic MTOR and EIF4E signaling pathways in NSCLC. These findings provided a novel insight into the clinical application of TRIM59. Therefore, TRIM59 may serve as an independent predictor for prognosis and a potential therapeutic target for NSCLC.
登录
查看更多内容
影响因子：
3.4
作者：
Liang, Jinqian;Xing, Dan;Li, Shugang
通讯作者：
Li, Shugang
影响因子：
5
作者：
Azim HA;Kassem L;Treilleux I;Wang Q;El Enein MA;Anis SE;Bachelot T
通讯作者：
Bachelot T
影响因子：
3.6
作者：
Koseoglu, Sandra;Lu, Zhuomei;Zou, Jun
通讯作者：
Zou, Jun
影响因子：
12.4
作者：
Liu, Ju;Zhang, C.;Feng, Z.
通讯作者：
Feng, Z.
影响因子：
3.1
作者：
Aierken G;Seyiti A;Alifu M;Kuerban G
通讯作者：
Kuerban G